Immunomedics Inc. About
Immunomedics Immunomedics’ mission is to improve patients’ health
and extend life by focusing on the development, manufacture and commercialization
of humanized monoclonal antibody-based products for the targeted treatment of
cancer, autoimmune and other serious diseases, guided by a principle of excellence,
and a culture of integrity and pride. Clinical
Trials for Immunomedics Products • CEA-Scan®
(arcitumomab) is a murine monoclonal IgG antibody Fab’ fragment that targets
tumors that have carcinoembryonic antigen (CEA) on their cell membrane. The
fragment is labeled with the isotope technetium-99m and images are produced using
a gamma camera. CEA-Scan can detect the presence, location and extent of metastasis
or recurrence of colorectal cancer. This product is approved in Australia, Canada,
Europe and the US . • LeukoScan® (sulesomab) is a murine monoclonal
IgG antibody Fab’ fragment labeled with the isotope technetium-99m. The fragment
targets NCA-90, found on the cell membrane of graunlocytes (a type of white blood
cell). Using a gamma camera, LeukoScan can be used to detect osteomyelitis (a
bone infection). LeukoScan is not available in North America, but it has European-wide
registration and it is also approved in Australia . • ImmuSTRIP is
an ELISA method immunoassay laboratory test kit used to detect Human Anti-Murine
Antibodies (HAMA). Using this kit, clinicians can determine if their patients
have preexisting HAMA or have developed HAMA due to recent treatments with murine
monoclonal antibodies. ImmuSTRIP is a simple to use test kit that provides results
in as little as one hour and is available for use by reference laboratories More
on Immunomedics Key
Statistics for Immunomedics